The group’s principle activities include acquiring, developing and marketing pathogen inactivation technology to produce biological products. The group products include Devitalized musculoskeletal tissue, allograft implants (tissue), Plasma protein therapeutics, and Clearant Process (R). The group operates from the United States.
